Compounding Matters Quarterly - Spring 2015

REFILL
Continued from Page 7
“NECC came as a complete shock to us,” said David Ball,
President of the firm. “In our many years of working with
the pharmacy profession, we saw the healing, helpful
work of compounding pharmacists. Now here was a
situation that didn’t just contain one element of a crisis,
it had virtually all of them: alleged violations of federal
and state law; cover-ups and obstructed investigations;
patient injuries and deaths; and investigators,
prosecutors, and former employees ready to talk about
the wanton disregard for professional standards and
horrific safety violations that occurred there.”
“We could not let the actions of NECC define this
profession,” Ball said. “We put in place a strategy that
maintained open lines of communications, provided
journalists with essential information, and we made clear
with our messaging that NECC in no way represented
what this industry is about; that NECC, according to the
government, was an illegal manufacturer disguised as a
compounding pharmacy to evade public oversight.”
“We also needed to remember at every turn,” Ball said,
“that this was a national tragedy that took the lives of 64
good people – mothers, fathers, sisters, brothers – and
that sickened almost 700. While the profession at large
and its association were not to blame, we had to be very
sensitive in everything that we said and did. The level of
human suffering, not only by the victims but among the
families that depended on them, was immense.”
The strategy enabled IACP to get a handle on the
situation and ultimately prevented that feared backlash.
While Congress did ultimately enact the Drug Quality
and Security Act, the law identified a continued vital role
for compounding pharmacy – a vast improvement over
earlier dialogue around eliminating the practice of sterile
compounding pharmacy altogether.
With the crisis under control, a second phase of the
strategy involved a media tour that enabled IACP to
educate the media and the public about the continued
need for compounding and that emphasized the high
quality work and rigorous standards currently in place.
One-on-one meetings were conducted with journalists
from Boston, New York, Washington, D.C., and Los
Angeles, and everywhere in between.
IACP and its members have emerged from the cloud
created by one rogue enterprise. The organization
has taken a position at the forefront of Congressional
dialogue over the implementation of the Drug Quality
and Security Act, and the profession continues to enjoy
significant growth.
Topi-CLICK® 140
Pain Management / Scar Care / HRT / Wound Care
NEW
for
2015
The Best
Just Got
Larger
CLICK-Assist - The Next Generation in Topical Dosing Technology
Topi-CLICK® 140
A proprietary Super-CLICKer mechanism is at the heart of this
2nd generation dosing system. This new technology provides
stronger audible CLICKs, heavier tactile sensations and improved
visual indicators.
140 mL Capacity 0.50 mL/CLICK 4X Larger than TC35
Topi-CLICK® 35
Topi-CLICK® 140
0.25 mL/CLICK
0.50 mL/CLICK
TOPICAL DOSING APPLICATOR
Protected by U.S. Patent Nos. 7,213,994 and 7,303,349
All items 2006-2015 by Custom RX TDA, LLC.
www.DoseLogix.com
As required for compounded prescription pharmaceuticals; verify the formulas
and the weight to volume conversions before dispensing to patients. The FDA
has not evaluated the Topi-CLICK® and use with prescription pharmaceuticals
should always be evaluated by a licensed pharmacist.
IACPRx.org/Publications | Spring 2015
9